Arendt advised Alvotech on a strategic USD 108 million convertible bond offering in the Nordic market
Experts involved in the Deal
Corporate Law, M&A
- Alexander Olliges
- Yannick Baer
Finance & Capital Markets
- Serge Zeien
- Sean Micallef-Trigona
Tax
- Jan Neugebauer
- Caroline Partoune
Arendt advised Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, on the Luxembourg law aspects of its USD 108 million senior unsecured convertible bond offering conducted on a private placement basis to qualified investors under Regulation S.
In parallel, a concurrent delta placement of existing Swedish Depositary Receipts (SDRs) was arranged to facilitate investor hedging, fully underwritten by two major shareholders.
Our team notably advised on all corporate, securities laws and tax aspects relating to the offering. Throughout the transaction, we worked seamlessly with counsel in Sweden (Roschier), Iceland (BBA//Fjeldco), the U.S. (Cooley LLP), and Norway (Thommessen AS advising DNB Carnegie as sole bookrunner) to ensure cohesive execution of this sophisticated cross-border offering.
Alvotech’s shares or SDRs are traded on Nasdaq Stockholm in Sweden, Nasdaq Global Market in the U.S. and Nasdaq Iceland Main Market in Iceland.